Enterprise Therapeutics Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. The proceeds will fund, in parallel, low molecular weight drug discovery and new target identification programs. The company will be based at the University of Sussex.
{iframe}http://www.news-medical.net/news/20150216/World-class-drug-discovery-team-launches-new-company-to-tackle-chronic-respiratory-disease.aspx{/iframe}